145 related articles for article (PubMed ID: 31600808)
41. LMWH in cancer patients with renal impairment - better than warfarin?
Bauersachs RM
Thromb Res; 2016 Apr; 140 Suppl 1():S160-4. PubMed ID: 27067971
[TBL] [Abstract][Full Text] [Related]
42. Perioperative Pharmacological Thromboprophylaxis in Patients With Cancer: A Systematic Review and Meta-analysis.
Guo Q; Huang B; Zhao J; Ma Y; Yuan D; Yang Y; Du X
Ann Surg; 2017 Jun; 265(6):1087-1093. PubMed ID: 27849664
[TBL] [Abstract][Full Text] [Related]
43. Anticoagulation for patients with cancer and central venous catheters.
Akl EA; Vasireddi SR; Gunukula S; Yosuico VE; Barba M; Sperati F; Cook D; Schünemann H
Cochrane Database Syst Rev; 2011 Feb; (2):CD006468. PubMed ID: 21328283
[TBL] [Abstract][Full Text] [Related]
44. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Geerts WH; Pineo GF; Heit JA; Bergqvist D; Lassen MR; Colwell CW; Ray JG
Chest; 2004 Sep; 126(3 Suppl):338S-400S. PubMed ID: 15383478
[TBL] [Abstract][Full Text] [Related]
45. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
46. The treatment of venous thromboembolism with low-molecular-weight heparins. A meta-analysis.
Bochenek T; Nizankowski R
Thromb Haemost; 2012 Apr; 107(4):699-716. PubMed ID: 22318218
[TBL] [Abstract][Full Text] [Related]
47. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials.
Alhazzani W; Lim W; Jaeschke RZ; Murad MH; Cade J; Cook DJ
Crit Care Med; 2013 Sep; 41(9):2088-98. PubMed ID: 23782973
[TBL] [Abstract][Full Text] [Related]
48. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
[TBL] [Abstract][Full Text] [Related]
49. Safe Use of Low-Molecular-weight Heparin in Pediatric Acute Lymphoblastic Leukemia and Lymphoma Around Lumbar Punctures.
Estepp JH; Smeltzer MP; Kang G; Howard SC; Reiss UM
J Pediatr Hematol Oncol; 2017 Nov; 39(8):596-601. PubMed ID: 28991127
[TBL] [Abstract][Full Text] [Related]
50. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Kahale L; Neumann I; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2014 Jun; (6):CD006649. PubMed ID: 24945634
[TBL] [Abstract][Full Text] [Related]
51. Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis.
Mai V; Bertoletti L; Cucherat M; Jardel S; Grange C; Provencher S; Lega JC
PLoS One; 2019; 14(4):e0214134. PubMed ID: 30933993
[TBL] [Abstract][Full Text] [Related]
52. Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis.
Rojas-Hernandez CM; Oo TH; García-Perdomo HA
J Thromb Thrombolysis; 2017 Feb; 43(2):233-240. PubMed ID: 27704333
[TBL] [Abstract][Full Text] [Related]
53. Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin.
Saccullo G; Malato A; Raso S; Santoro M; Zammit V; Casuccio A; Siragusa S
Am J Hematol; 2012 Apr; 87(4):388-91. PubMed ID: 22374861
[TBL] [Abstract][Full Text] [Related]
54. Clinical Effectiveness of Aspirin as Multimodal Thromboprophylaxis in Primary Total Hip and Knee Arthroplasty: A Review of 6078 Cases.
Ghosh A; Best AJ; Rudge SJ; Chatterji U
J Arthroplasty; 2019 Jul; 34(7):1359-1363. PubMed ID: 30982759
[TBL] [Abstract][Full Text] [Related]
55. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis.
Connell NT; Abel GA; Connors JM
Thromb Res; 2017 Feb; 150():53-58. PubMed ID: 28039844
[TBL] [Abstract][Full Text] [Related]
56. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Geerts WH; Bergqvist D; Pineo GF; Heit JA; Samama CM; Lassen MR; Colwell CW
Chest; 2008 Jun; 133(6 Suppl):381S-453S. PubMed ID: 18574271
[TBL] [Abstract][Full Text] [Related]
57. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group.
Kakkar VV; Cohen AT; Edmonson RA; Phillips MJ; Cooper DJ; Das SK; Maher KT; Sanderson RM; Ward VP; Kakkar S
Lancet; 1993 Jan; 341(8840):259-65. PubMed ID: 8093915
[TBL] [Abstract][Full Text] [Related]
58. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
[TBL] [Abstract][Full Text] [Related]
59. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
van der Heijden JF; Hutten BA; Büller HR; Prins MH
Cochrane Database Syst Rev; 2002; (1):CD002001. PubMed ID: 11869618
[TBL] [Abstract][Full Text] [Related]
60. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Stepien K; Nowak K; Zalewski J; Pac A; Undas A
Vascul Pharmacol; 2019 Sep; 120():106567. PubMed ID: 31158568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
